Vertex Pharmaceuticals Stock Analysis

VRTX Stock  USD 509.04  2.70  0.53%   
Vertex Pharmaceuticals is undervalued with Real Value of 569.7 and Target Price of 492.97. The main objective of Vertex Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Vertex Pharmaceuticals is worth, separate from its market price. There are two main types of Vertex Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Vertex Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Vertex Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Vertex Stock trading window is adjusted to America/New York timezone.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Vertex Stock Analysis Notes

About 97.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.44. Vertex Pharmaceuticals recorded a loss per share of 2.09. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people. For more information please call MD FASN at 617 341 6100 or visit https://www.vrtx.com.

Vertex Pharmaceuticals Quarterly Total Revenue

2.91 Billion

Vertex Pharmaceuticals Investment Alerts

The company reported the previous year's revenue of 11.02 B. Net Loss for the year was (535.6 M) with profit before overhead, payroll, taxes, and interest of 6.02 B.
Vertex Pharmaceuticals currently holds about 9.77 B in cash with (492.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 38.06.
Over 97.0% of the company outstanding shares are owned by institutional investors
Latest headline from seekingalpha.com: Vertex Resource Group Ltd. reports Q4 results

Vertex Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Vertex Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
5th of February 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Vertex Largest EPS Surprises

Earnings surprises can significantly impact Vertex Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2013-01-29
2012-12-31-0.08-0.09-0.0112 
2016-10-25
2016-09-300.180.16-0.0211 
2000-02-16
1999-12-310.010.030.02200 
View All Earnings Estimates

Vertex Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Vertex Pharmaceuticals' ESG score is a quantitative measure that evaluates Vertex Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Vertex Pharmaceuticals' operations that may have significant financial implications and affect Vertex Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Vertex Stock Institutional Investors

Shares
Loomis, Sayles & Company Lp2024-12-31
3.8 M
Norges Bank2024-12-31
3.4 M
Amundi2024-12-31
3.3 M
Morgan Stanley - Brokerage Accounts2024-12-31
3.2 M
Edgewood Management Llc2024-12-31
M
Hhg Plc2024-12-31
2.8 M
Northern Trust Corp2024-12-31
2.7 M
Bank Of America Corp2024-12-31
2.4 M
Ubs Asset Mgmt Americas Inc2024-12-31
2.3 M
Capital World Investors2024-12-31
28.3 M
Vanguard Group Inc2024-12-31
23.3 M
Note, although Vertex Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vertex Market Capitalization

The company currently falls under 'Mega-Cap' category with a current market capitalization of 131.41 B.

Vertex Profitablity

The company has Profit Margin (PM) of (0.05) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.45 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.45.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.03)(0.03)
Return On Capital Employed(0.01)(0.01)
Return On Assets(0.02)(0.02)
Return On Equity(0.03)(0.03)

Management Efficiency

Vertex Pharmaceuticals has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0315) %, meaning that it created substantial loss on money invested by shareholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.03 in 2025. Return On Capital Employed is likely to drop to -0.01 in 2025. At this time, Vertex Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 13.6 B in 2025, whereas Intangible Assets are likely to drop slightly above 454.9 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 63.73  66.91 
Tangible Book Value Per Share 56.29  59.11 
Enterprise Value Over EBITDA 207.43  217.81 
Price Book Value Ratio 6.32  7.39 
Enterprise Value Multiple 207.43  217.81 
Price Fair Value 6.32  7.39 
Enterprise Value15.8 B8.3 B
Understanding the operational decisions made by Vertex Pharmaceuticals management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Operating Margin
0.4498
Profit Margin
(0.05)
Beta
0.415
Return On Assets
0.1268
Return On Equity
(0.03)

Technical Drivers

As of the 26th of March, Vertex Pharmaceuticals has the Coefficient Of Variation of 1452.64, semi deviation of 2.54, and Risk Adjusted Performance of 0.0641. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vertex Pharmaceuticals, as well as the relationship between them.

Vertex Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Vertex Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Vertex Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Vertex Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vertex Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vertex Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vertex Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Vertex Pharmaceuticals Outstanding Bonds

Vertex Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vertex Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vertex bonds can be classified according to their maturity, which is the date when Vertex Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Vertex Pharmaceuticals Predictive Daily Indicators

Vertex Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vertex Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Vertex Pharmaceuticals Corporate Filings

F4
17th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
12th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
6th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
5th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
28th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
26th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
24th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
19th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Vertex Pharmaceuticals Forecast Models

Vertex Pharmaceuticals' time-series forecasting models are one of many Vertex Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vertex Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Vertex Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vertex Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vertex shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vertex Pharmaceuticals. By using and applying Vertex Stock analysis, traders can create a robust methodology for identifying Vertex entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.02  0.02 
Operating Profit Margin(0.02)(0.02)
Net Loss(0.05)(0.05)
Gross Profit Margin 0.86  1.09 

Current Vertex Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vertex analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vertex analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
492.97Buy35Odds
Vertex Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Vertex analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Vertex stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Vertex Pharmaceuticals, talking to its executives and customers, or listening to Vertex conference calls.
Vertex Analyst Advice Details

Vertex Stock Analysis Indicators

Vertex Pharmaceuticals stock analysis indicators help investors evaluate how Vertex Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vertex Pharmaceuticals shares will generate the highest return on investment. By understating and applying Vertex Pharmaceuticals stock analysis, traders can identify Vertex Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow10.4 B
Common Stock Shares Outstanding257.9 M
Total Stockholder Equity16.4 B
Tax Provision784.1 M
Quarterly Earnings Growth Y O Y-0.056
Property Plant And Equipment Net2.6 B
Cash And Short Term Investments6.1 B
Cash4.6 B
Accounts Payable413 M
Net Debt-2.8 B
50 Day M A470.6866
Total Current Liabilities3.6 B
Other Operating Expenses11.3 B
Non Current Assets Total12.9 B
Forward Price Earnings29.8507
Non Currrent Assets Other999.3 M
Stock Based Compensation698.5 M

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.